The Ozempic Effect Is Starting to Show Up in Obesity Data

For decades, the obesity trend in the United States seemed to move in only one direction. Gallup's long-running survey had self-reported adult obesity rising from 25.5% in 2008 to 39.9% in 2022. The newest finding is therefore meaningful even if it is still early: the rate fell to 37% in 2025, a drop of nearly three points in a measure that had mostly climbed for years.

The most plausible explanation in the reporting is scale. More adults are using GLP-1 medicines, and the survey cited by Vox found that more than 12% of adults reported taking them in the second and third quarters of 2025, up from less than 6% in early 2024. These medicines reduce appetite signals, slow gastric emptying, and improve post-meal insulin signaling; when enough people use drugs that can produce double-digit average weight loss in trials, national data can begin to move.

That does not make the number a final verdict. Self-reported weight is imperfect, and public-health confirmation from stronger federal data still matters. The story also keeps the downsides in view: cost, access, side effects, long-term treatment, and the likelihood of regain when therapy stops. A population signal can be encouraging and still leave the hardest practical questions unresolved, so it should be read as public-health context, not medical advice or a prescription.

The useful takeaway is that the argument has shifted. GLP-1s are no longer only a private medical decision or a celebrity-culture symbol; they may be large enough to affect population health statistics. Whether that becomes lasting public-health progress depends on who can get treatment, who can stay on it safely, and whether better formats and lower prices make the benefits less dependent on income.

Read the full story at Vox ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.